MedTrace Logo

Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy

NCT03391830 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2021-01-12

No results posted yet for this study

Summary

To evaluate the benefit for statin use in prevention of of CI-AKI after computed tomography urogram (CTU).

Conditions

  • Contrast-induced Nephropathy
  • Statin
  • Ascorbic Acid
  • AKI

Interventions

DRUG

Atorvastatin-Ascorbic acid

atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Yasser Othman, MD · Urology and nephrology center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-15
Primary Completion
2020-01-01
Completion
2020-01-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03391830 on ClinicalTrials.gov